Abstract
AbstractProstate cancer is one of the most prevalent forms of cancer around the world. Androgen-deprivation treatment and chemotherapy are the curative approaches used to suppress prostate cancer progression. However, drug resistance is extensively and hard to overcome even though remarkable progress has been made in recent decades. Noncoding RNAs, such as miRNAs, lncRNAs, and circRNAs, are a group of cellular RNAs which participate in various cellular processes and diseases. Recently, accumulating evidence has highlighted the vital role of non-coding RNA in the development of drug resistance in prostate cancer. In this review, we summarize the important roles of these three classes of noncoding RNA in drug resistance and the potential therapeutic applications in this disease.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Cell Biology,Cellular and Molecular Neuroscience,Immunology
Reference109 articles.
1. Attard, G. et al. Prostate cancer. Lancet 387, 70–82 (2016).
2. Marugame, T. & Katanoda, K. International comparisons of cumulative risk of breast and prostate cancer, from cancer incidence in five continents vol. VIII. Jpn. J. Clin. Oncol. 36, 399–400 (2006).
3. Cuzick, J. et al. Prevention and early detection of prostate cancer. Lancet Oncol. 15, e484–e492 (2014).
4. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J. Clin. 68, 394–424 (2018).
5. Li, F. & Mahato, R. I. MicroRNAs and drug resistance in prostate cancers. Mol. Pharm. 11, 2539–2552 (2014).
Cited by
45 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献